The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia
NCT04157959 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2019-11-08
Summary
The objective of the study is to assess the pharmacodynamic properties of drug-drug of SHR4640 and Febuxostat interaction in patients with Hyperuricemia.
Conditions
- Hyperuricemia
Interventions
- DRUG
-
SHR4640 dose1
Tablet,dose1,QD
- DRUG
-
Febuxostat dose2
Tablet,dose2,QD
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-14
- Primary Completion
- 2020-06-01
- Completion
- 2020-06-30
Countries
- China
Study Locations
More Related Trials
-
Multiple Dose Study of SHR4640 in Healthy Subjects
NCT02890966 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Hyperuricaemia on Chronic Renal Disease
NCT03425708 ·Status: UNKNOWN ·Phase: PHASE4
-
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
NCT06196580 ·Status: COMPLETED ·Phase: PHASE1
-
Hyperuricemia and Diabetic Nephropathy
NCT04799925 ·Status: UNKNOWN
-
Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)
NCT02837198 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
NCT02252835 ·Status: COMPLETED ·Phase: PHASE2
-
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
NCT03375632 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04052932 ·Status: COMPLETED ·Phase: PHASE3
-
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02344862 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level
NCT03211403 ·Status: COMPLETED ·Phase: PHASE1
-
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04956432 ·Status: COMPLETED ·Phase: PHASE3
-
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
NCT01416402 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects
NCT07324434 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
NCT02082769 ·Status: COMPLETED ·Phase: PHASE3
-
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03372200 ·Status: COMPLETED ·Phase: PHASE3
-
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02416167 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients
NCT03149939 ·Status: COMPLETED ·Phase: NA
-
Study of FYU-981 in Hyperuricemia With or Without Gout
NCT03006445 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Dotinurad in Hyperuricemia With Hypertension
NCT06834230 ·Status: RECRUITING ·Phase: PHASE4
-
Role of Uralyt-U in Patients With Hyperuricemia
NCT04352153 ·Status: UNKNOWN ·Phase: NA
-
Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
NCT01082640 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
NCT06139393 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
NCT06414837 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy
NCT01984749 ·Status: UNKNOWN ·Phase: NA
-
A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
NCT02317861 ·Status: COMPLETED ·Phase: PHASE1/PHASE2